=== Population Extract 1 (Population) ===
ion
nificant increase in PFS but only a slight trend of OS
improvement with the combination [71–73] (I,B). First‑line setting
• Combination of pemetrexed-carboplatin and gefitinib has
demonstrated a significant increase in PFS and OS in • First-line treatment with ALK TKIs is the preferred
japanese population [74] (I,B). treatment (I,A). Crizotinib and ceritinib have shown a
significant statistical improvement in terms of PFS and ROS‑1 and other rare targetable genetic alterations
RR compared with chemotherapy in randomized phase
III trials (I,A) [79, 80]. • Crizotinib is indicated for the treatment of

=== Population Extract 2 (Patients) ===
on-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the develop-
ment of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper
molecular knowledge; so, more options can be offered to patients with driver mutations. Groups with specific treatments
account for around 25% and demonstrate significant increases in overall survival, and in some subgroups, it is important
to evaluate each treatment alternative in accordance with scientific evidence, and even more so with immunotherapy. New
tre

=== Population Extract 3 (Patients) ===
o assign levels of evi- function.
dence and grades of recommendation. • Bronchoscopy.
• Chest and upper abdomen (including liver and adrenal
Diagnosis glands) computerized tomography (CT).
• Brain CT or magnetic resonance imaging (MRI) is rec-
Diagnosis: pathology and molecular testing ommended for patients undergoing radical treatment,
in patients with EGFR mutation or ALK translocation
The pathological diagnosis of non-small cell lung cancer or if there are neurological symptoms in the physical
(NSCLC) should be made according to the World Health examination.
Organization (WHO) classification [1]. T

=== Population Extract 4 (Patients) ===
d grades of recommendation. • Bronchoscopy.
• Chest and upper abdomen (including liver and adrenal
Diagnosis glands) computerized tomography (CT).
• Brain CT or magnetic resonance imaging (MRI) is rec-
Diagnosis: pathology and molecular testing ommended for patients undergoing radical treatment,
in patients with EGFR mutation or ALK translocation
The pathological diagnosis of non-small cell lung cancer or if there are neurological symptoms in the physical
(NSCLC) should be made according to the World Health examination.
Organization (WHO) classification [1]. The International • Bone scan is recommende

=== Population Extract 5 (Patients) ===
World Health examination.
Organization (WHO) classification [1]. The International • Bone scan is recommended if there is bone pain, high
Association for the Study of Lung Cancer (IASLC) provided serum calcium or high alkaline phosphatase.
adenocarcinoma classification as well as key recommenda- In patients undergoing potentially radical treatment,
tions for the management of small biopsies and cytology [2]. additional recommendations should be considered:
For therapeutic implications, specific subtyping of NSCLC is • Whole-body FDG-positron emission tomography
strongly recommended whenever possible.

=== Population Extract 6 (Patients) ===
ve mediastinal staging, endobronchial ultra-
of NSCLC advanced disease is recommended in daily clinical sound-guided fine-needle aspiration and/or endo-
practice by both ESMO [4] and ASCO [5] guidelines, as it has scopic ultrasound-guided fine-needle aspiration are
demonstrated to have an impact on patients’ outcomes (I,A). recommended in patients with suspected mediastinal or
New molecular guidelines recommend to include upfront hilar lymph nodes (LNs) in the PET–CT. For patients
ROS-1 testing along with EGFR and ALK in stage IV non- with suspected LNs on PET–CT and negative EBUS/
SCC and endorse to

=== Population Extract 7 (Patients) ===
ra-
of NSCLC advanced disease is recommended in daily clinical sound-guided fine-needle aspiration and/or endo-
practice by both ESMO [4] and ASCO [5] guidelines, as it has scopic ultrasound-guided fine-needle aspiration are
demonstrated to have an impact on patients’ outcomes (I,A). recommended in patients with suspected mediastinal or
New molecular guidelines recommend to include upfront hilar lymph nodes (LNs) in the PET–CT. For patients
ROS-1 testing along with EGFR and ALK in stage IV non- with suspected LNs on PET–CT and negative EBUS/
SCC and endorse to include other additional genes such as EU

=== Population Extract 8 (Patients) ===
] and ASCO [5] guidelines, as it has scopic ultrasound-guided fine-needle aspiration are
demonstrated to have an impact on patients’ outcomes (I,A). recommended in patients with suspected mediastinal or
New molecular guidelines recommend to include upfront hilar lymph nodes (LNs) in the PET–CT. For patients
ROS-1 testing along with EGFR and ALK in stage IV non- with suspected LNs on PET–CT and negative EBUS/
SCC and endorse to include other additional genes such as EUS results, an additional mediastinoscopy is recom-
BRAF, MET, HER2, KRAS and RET for laboratories that mended. In patients with no suspe

=== Population Extract 9 (Patients) ===
e PET–CT. For patients
ROS-1 testing along with EGFR and ALK in stage IV non- with suspected LNs on PET–CT and negative EBUS/
SCC and endorse to include other additional genes such as EUS results, an additional mediastinoscopy is recom-
BRAF, MET, HER2, KRAS and RET for laboratories that mended. In patients with no suspected LN on the PET-
perform next-generation sequencing (NGS) testing [5]. Immu- CT, invasive mediastinal staging is also recommended
nohistochemistry can be considered as an alternative to fluo- in patients with enlarged mediastinal LNs (≥ 1.5 cm),
rescence in situ hybridization for AL

=== Population Extract 10 (Patients) ===
oscopy is recom-
BRAF, MET, HER2, KRAS and RET for laboratories that mended. In patients with no suspected LN on the PET-
perform next-generation sequencing (NGS) testing [5]. Immu- CT, invasive mediastinal staging is also recommended
nohistochemistry can be considered as an alternative to fluo- in patients with enlarged mediastinal LNs (≥ 1.5 cm),
rescence in situ hybridization for ALK and/or ROS1 testing. in tumors ≥ 3 cm and/or in patients with central tumors.
In EGFR mutant patients progressing on first- or second- • Histological and cytological confirmation is strongly
generation EGFR TKI, the de

=== Population Extract 11 (Patients) ===
eration sequencing (NGS) testing [5]. Immu- CT, invasive mediastinal staging is also recommended
nohistochemistry can be considered as an alternative to fluo- in patients with enlarged mediastinal LNs (≥ 1.5 cm),
rescence in situ hybridization for ALK and/or ROS1 testing. in tumors ≥ 3 cm and/or in patients with central tumors.
In EGFR mutant patients progressing on first- or second- • Histological and cytological confirmation is strongly
generation EGFR TKI, the detection of EGFR T790M second- recommended in the presence of pleural/pericardial
ary resistance mutations in tumor tissue is recommended (

=== Population Extract 12 (Patients) ===
T, invasive mediastinal staging is also recommended
nohistochemistry can be considered as an alternative to fluo- in patients with enlarged mediastinal LNs (≥ 1.5 cm),
rescence in situ hybridization for ALK and/or ROS1 testing. in tumors ≥ 3 cm and/or in patients with central tumors.
In EGFR mutant patients progressing on first- or second- • Histological and cytological confirmation is strongly
generation EGFR TKI, the detection of EGFR T790M second- recommended in the presence of pleural/pericardial
ary resistance mutations in tumor tissue is recommended (I,A). effusion or isolated metastatic site.
L

=== Population Extract 13 (Patients) ===
tations in tumor tissue is recommended (I,A). effusion or isolated metastatic site.
Liquid biopsies or molecular DNA profiling in blood (ctDNA)
is currently accepted as a good surrogate for EGFR testing in
tissue (II,A), enabling clinicians to collect samples in a non- invasive approach [6, 7].
All patients with advanced NSCLC should, at baseline,
have their tissue assessed for programmed cell death 1 ligand During the 16th World Congress of Lung Cancer, the
(PD-L1) expression by IHC test for selecting patients for anti- International Association for the Study of Lung Cancer
programmed death 1 (PD-1)

=== Population Extract 14 (Patients) ===
ssue (II,A), enabling clinicians to collect samples in a non- invasive approach [6, 7].
All patients with advanced NSCLC should, at baseline,
have their tissue assessed for programmed cell death 1 ligand During the 16th World Congress of Lung Cancer, the
(PD-L1) expression by IHC test for selecting patients for anti- International Association for the Study of Lung Cancer
programmed death 1 (PD-1) or anti-PD-L1 treatment [8]. (IASLC) proposed the TNM 8th edition that was accepted
by the Union for International Cancer Control (UICC) and
Disease staging the American Joint Committee on Cancer (AJCC) [9].

=== Population Extract 15 (Patients) ===
0
IA1 T1a(mi)/T1a N0 M0
IA2 T1b N0 M0
IA3 T1c N0 M0
IB T2a N0 M0
IIA T2b N0 M0
IIB T1a-T2b N1 M0
T3 N0 M0
IIIA T1a-T2b N2 M0
T3 N1 M0
T4 N0/N1 M0
IIIB T1a-T2b N3 M0
T3/T4 N2 M0
IIIC T3/T4 N3 M0
IVA Any T Any N M1a/M1
IVB Any T Any N M1c
Stage I–II
A multidisciplinary tumor board evaluation of NSCLC
patients with stage I-II disease is strongly recommended
even non-surgical patients. It has to include a preoperativ
cardiopulmonary assessment.
Surgery
For stage I–II NSCLC patients and no medical contraindi
cations to surgery, surgical resection remains the treatmen
of choice, yielding the best potential

=== Population Extract 16 (Patients) ===
M0
IIB T1a-T2b N1 M0
T3 N0 M0
IIIA T1a-T2b N2 M0
T3 N1 M0
T4 N0/N1 M0
IIIB T1a-T2b N3 M0
T3/T4 N2 M0
IIIC T3/T4 N3 M0
IVA Any T Any N M1a/M1
IVB Any T Any N M1c
Stage I–II
A multidisciplinary tumor board evaluation of NSCLC
patients with stage I-II disease is strongly recommended
even non-surgical patients. It has to include a preoperativ
cardiopulmonary assessment.
Surgery
For stage I–II NSCLC patients and no medical contraindi
cations to surgery, surgical resection remains the treatmen
of choice, yielding the best potential choice of cure fo
these patients (IB).
The type of surgery resection depend

=== Population Extract 17 (Patients) ===
M0
IIIC T3/T4 N3 M0
IVA Any T Any N M1a/M1
IVB Any T Any N M1c
Stage I–II
A multidisciplinary tumor board evaluation of NSCLC
patients with stage I-II disease is strongly recommended
even non-surgical patients. It has to include a preoperativ
cardiopulmonary assessment.
Surgery
For stage I–II NSCLC patients and no medical contraindi
cations to surgery, surgical resection remains the treatmen
of choice, yielding the best potential choice of cure fo
these patients (IB).
The type of surgery resection depends on the extensio
of the disease, the location of the tumor and the preopera
tive evaluation:
• In

=== Population Extract 18 (Patients) ===
is strongly recommended
even non-surgical patients. It has to include a preoperativ
cardiopulmonary assessment.
Surgery
For stage I–II NSCLC patients and no medical contraindi
cations to surgery, surgical resection remains the treatmen
of choice, yielding the best potential choice of cure fo
these patients (IB).
The type of surgery resection depends on the extensio
of the disease, the location of the tumor and the preopera
tive evaluation:
• In stage I–II medically fit NSCLC patients, lobectom
or anatomic pulmonary resection is recommende
rather than sublobar resection (I,B). Systematic medi
astinal

=== Population Extract 19 (Patients) ===
ons to surgery, surgical resection remains the treatmen
of choice, yielding the best potential choice of cure fo
these patients (IB).
The type of surgery resection depends on the extensio
of the disease, the location of the tumor and the preopera
tive evaluation:
• In stage I–II medically fit NSCLC patients, lobectom
or anatomic pulmonary resection is recommende
rather than sublobar resection (I,B). Systematic medi
astinal lymph node dissection is recommended ove
selective sampling lymph node dissection for accu
rate pathologic staging [10] (IB). For stage II patient
undergoing anatomic resection, med

=== Population Extract 20 (Patients) ===
tinal lymp
node dissection may provide additional survival benefi
over sampling [11] (II,B).
• A sublobar resection (anatomical segmentectomy) i
recommended over nonsurgical therapy for patient
who cannot tolerate a lobar resection due to decrease
pulmonary function or comorbid disease (I,B).
• For patients with a stage I predominantly ground glass
opacity with lesion ≤ 1 cm, sublobar resection with nega-
tive margins is suggested over lobectomy (I,B).
• Reresection is recommended for patients with positive
margins in resected stage I–II NSCLC patients. If it is not
possible, postoperative radiotherap

=== Population Extract 21 (Patients) ===
ent
who cannot tolerate a lobar resection due to decrease
pulmonary function or comorbid disease (I,B).
• For patients with a stage I predominantly ground glass
opacity with lesion ≤ 1 cm, sublobar resection with nega-
tive margins is suggested over lobectomy (I,B).
• Reresection is recommended for patients with positive
margins in resected stage I–II NSCLC patients. If it is not
possible, postoperative radiotherapy may be considered
Adjuvant therapy
Overall survival (OS) benefit of adjuvant treatment is limited
to cisplatin-based chemotherapy in completely resected fit
stage II–III patients [13].
• F

=== Population Extract 22 (Patients) ===
lmonary function or comorbid disease (I,B).
• For patients with a stage I predominantly ground glass
opacity with lesion ≤ 1 cm, sublobar resection with nega-
tive margins is suggested over lobectomy (I,B).
• Reresection is recommended for patients with positive
margins in resected stage I–II NSCLC patients. If it is not
possible, postoperative radiotherapy may be considered
Adjuvant therapy
Overall survival (OS) benefit of adjuvant treatment is limited
to cisplatin-based chemotherapy in completely resected fit
stage II–III patients [13].
• Four cycles of cisplatin-based chemotherapy following
complet

=== Population Extract 23 (Patients) ===
ended for patients with positive
margins in resected stage I–II NSCLC patients. If it is not
possible, postoperative radiotherapy may be considered
Adjuvant therapy
Overall survival (OS) benefit of adjuvant treatment is limited
to cisplatin-based chemotherapy in completely resected fit
stage II–III patients [13].
• Four cycles of cisplatin-based chemotherapy following
complete resection in stage II NSCLC patients remain
the standard of care in adjuvant setting, offering a 5% OS
benefit [13] (I,A).
1b
• Stage I (7th TNM edition) NSCLC patients do not ben-
efit from adjuvant therapy except those patient

=== Population Extract 24 (Patients) ===
perative radiotherapy may be considered
Adjuvant therapy
Overall survival (OS) benefit of adjuvant treatment is limited
to cisplatin-based chemotherapy in completely resected fit
stage II–III patients [13].
• Four cycles of cisplatin-based chemotherapy following
complete resection in stage II NSCLC patients remain
the standard of care in adjuvant setting, offering a 5% OS
benefit [13] (I,A).
1b
• Stage I (7th TNM edition) NSCLC patients do not ben-
efit from adjuvant therapy except those patients with
tumors > 4 cm [5, 14] (I,C).
• In elderly fit patients, adjuvant platinum-based chemo-
therapy should

=== Population Extract 25 (Patients) ===
-based chemotherapy in completely resected fit
stage II–III patients [13].
• Four cycles of cisplatin-based chemotherapy following
complete resection in stage II NSCLC patients remain
the standard of care in adjuvant setting, offering a 5% OS
benefit [13] (I,A).
1b
• Stage I (7th TNM edition) NSCLC patients do not ben-
efit from adjuvant therapy except those patients with
tumors > 4 cm [5, 14] (I,C).
• In elderly fit patients, adjuvant platinum-based chemo-
therapy should be considered.
• Postoperative radiotherapy (PORT) is not indicated in
C
completely resected stage I–II NSCLC patients [15] (I,A-
d

=== Population Extract 26 (Patients) ===
atients [13].
• Four cycles of cisplatin-based chemotherapy following
complete resection in stage II NSCLC patients remain
the standard of care in adjuvant setting, offering a 5% OS
benefit [13] (I,A).
1b
• Stage I (7th TNM edition) NSCLC patients do not ben-
efit from adjuvant therapy except those patients with
tumors > 4 cm [5, 14] (I,C).
• In elderly fit patients, adjuvant platinum-based chemo-
therapy should be considered.
• Postoperative radiotherapy (PORT) is not indicated in
C
completely resected stage I–II NSCLC patients [15] (I,A-
d,
II,A).
ve Preoperative chemotherapy has the potential role

=== Population Extract 27 (Patients) ===
following
complete resection in stage II NSCLC patients remain
the standard of care in adjuvant setting, offering a 5% OS
benefit [13] (I,A).
1b
• Stage I (7th TNM edition) NSCLC patients do not ben-
efit from adjuvant therapy except those patients with
tumors > 4 cm [5, 14] (I,C).
• In elderly fit patients, adjuvant platinum-based chemo-
therapy should be considered.
• Postoperative radiotherapy (PORT) is not indicated in
C
completely resected stage I–II NSCLC patients [15] (I,A-
d,
II,A).
ve Preoperative chemotherapy has the potential role to reduce
tumor size, increase operability, and eliminate mi

=== Population Extract 28 (Patients) ===
ition) NSCLC patients do not ben-
efit from adjuvant therapy except those patients with
tumors > 4 cm [5, 14] (I,C).
• In elderly fit patients, adjuvant platinum-based chemo-
therapy should be considered.
• Postoperative radiotherapy (PORT) is not indicated in
C
completely resected stage I–II NSCLC patients [15] (I,A-
d,
II,A).
ve Preoperative chemotherapy has the potential role to reduce
tumor size, increase operability, and eliminate micrometas-
i- tases. A meta-analysis with 15 randomized trials showed
nt a significant benefit of preoperative chemotherapy on OS
or (representing an absolute survival

=== Population Extract 29 (Patients) ===
urvival improvement of 5% at
5 years [16]. Although neoadjuvant chemotherapy has simi-
on lar impact on OS than adjuvant chemotherapy, more conclu-
a- sive evidence favors adjuvant treatment (I,B).
Stereotactic ablative radiotherapy (SART)
my
ed
SART is recommended for medically inoperable NSCLC
i-
patients with node negative tumors ≤5 cm (2C). Several non-
er
randomized studies suggest that SART might be a suitable
u-
option for operable patients older than 75 years [17] (II,C).
ts
ph
Other adjuvant treatments
fit
is Adjuvant EGFR TKI in patients with EGFR mutation has
ts not demonstrated a survival

=== Population Extract 30 (Patients) ===
clu-
a- sive evidence favors adjuvant treatment (I,B).
Stereotactic ablative radiotherapy (SART)
my
ed
SART is recommended for medically inoperable NSCLC
i-
patients with node negative tumors ≤5 cm (2C). Several non-
er
randomized studies suggest that SART might be a suitable
u-
option for operable patients older than 75 years [17] (II,C).
ts
ph
Other adjuvant treatments
fit
is Adjuvant EGFR TKI in patients with EGFR mutation has
ts not demonstrated a survival benefit yet. Several trials in
ed patients with EGFR mutations or ALK translocations in
adjuvant setting are ongoing [18]. Stage III NSCLC is a

=== Population Extract 31 (Patients) ===
SART is recommended for medically inoperable NSCLC
i-
patients with node negative tumors ≤5 cm (2C). Several non-
er
randomized studies suggest that SART might be a suitable
u-
option for operable patients older than 75 years [17] (II,C).
ts
ph
Other adjuvant treatments
fit
is Adjuvant EGFR TKI in patients with EGFR mutation has
ts not demonstrated a survival benefit yet. Several trials in
ed patients with EGFR mutations or ALK translocations in
adjuvant setting are ongoing [18]. Stage III NSCLC is a heterogeneous and complex disease Unresectable LA-NSCLC includes stage IIIA N2 (bulky
that has been c

=== Population Extract 32 (Patients) ===
2C). Several non-
er
randomized studies suggest that SART might be a suitable
u-
option for operable patients older than 75 years [17] (II,C).
ts
ph
Other adjuvant treatments
fit
is Adjuvant EGFR TKI in patients with EGFR mutation has
ts not demonstrated a survival benefit yet. Several trials in
ed patients with EGFR mutations or ALK translocations in
adjuvant setting are ongoing [18]. Stage III NSCLC is a heterogeneous and complex disease Unresectable LA-NSCLC includes stage IIIA N2 (bulky
that has been classified into different subgroups: resectable, and/or multiple nodal involvement), stage IIIB an

=== Population Extract 33 (Patients) ===
s: resectable, and/or multiple nodal involvement), stage IIIB and IIIC.
potentially resectable and unresectable locally advanced
NSCLC. Treatment decision should be taken by an experi- • Concurrent chemoradiotherapy is the treatment of choice
enced multidisciplinary team (Fig. 1). for medically fit patients (I,A). Several randomized clini-
cal trials and a meta-analysis have shown a higher 5-year
Resectable and potentially resectable NSCLC survival rates favoring this strategy over sequential
approaches [24].
• In patients with R0 resected stage III NSCLC, 4 cycles of • Cisplatin-based combinations ar

=== Population Extract 34 (Patients) ===
he treatment of choice
enced multidisciplinary team (Fig. 1). for medically fit patients (I,A). Several randomized clini-
cal trials and a meta-analysis have shown a higher 5-year
Resectable and potentially resectable NSCLC survival rates favoring this strategy over sequential
approaches [24].
• In patients with R0 resected stage III NSCLC, 4 cycles of • Cisplatin-based combinations are recommended for med-
adjuvant platinum-based chemotherapy should be given ically fit patients (usually with etoposide or vinorelbine)
(preferably cisplatin doublet) [19] (I,A). [24].
• In patients with pathological N2

=== Population Extract 35 (Patients) ===
year
Resectable and potentially resectable NSCLC survival rates favoring this strategy over sequential
approaches [24].
• In patients with R0 resected stage III NSCLC, 4 cycles of • Cisplatin-based combinations are recommended for med-
adjuvant platinum-based chemotherapy should be given ically fit patients (usually with etoposide or vinorelbine)
(preferably cisplatin doublet) [19] (I,A). [24].
• In patients with pathological N2 NSCLC, PORT appears • Radiotherapy is usually given at a dose of 60–66 Gy in
to improve OS in non-randomized analysis, and it is usu- 30–33 fractions over 6–7 weeks. Higher do

=== Population Extract 36 (Patients) ===
approaches [24].
• In patients with R0 resected stage III NSCLC, 4 cycles of • Cisplatin-based combinations are recommended for med-
adjuvant platinum-based chemotherapy should be given ically fit patients (usually with etoposide or vinorelbine)
(preferably cisplatin doublet) [19] (I,A). [24].
• In patients with pathological N2 NSCLC, PORT appears • Radiotherapy is usually given at a dose of 60–66 Gy in
to improve OS in non-randomized analysis, and it is usu- 30–33 fractions over 6–7 weeks. Higher doses are not
ally administered after adjuvant chemotherapy (II,A). recommended outside of clinical trial

=== Population Extract 37 (Patients) ===
gical N2 NSCLC, PORT appears • Radiotherapy is usually given at a dose of 60–66 Gy in
to improve OS in non-randomized analysis, and it is usu- 30–33 fractions over 6–7 weeks. Higher doses are not
ally administered after adjuvant chemotherapy (II,A). recommended outside of clinical trials [25].
• In patients with potentially resectable disease, the opti- • If concurrent chemoradiotherapy is not feasible due to
mal treatment strategy remains unclear. Several phase poor performance status, comorbidities, and/or unfit
III trials and a meta-analysis showed that induction ther- patients, a sequential approa

=== Population Extract 38 (Patients) ===
al trials [25].
• In patients with potentially resectable disease, the opti- • If concurrent chemoradiotherapy is not feasible due to
mal treatment strategy remains unclear. Several phase poor performance status, comorbidities, and/or unfit
III trials and a meta-analysis showed that induction ther- patients, a sequential approach is a reasonable option
apy followed by surgery might be better than surgery [26].
alone [20]. Surgery has been compared to radiotherapy • There is no role for prophylactic cranial irradiation in
in patients with tumor response after induction chemo- stage III (II,A).
therapy,

=== Population Extract 39 (Patients) ===
d/or unfit
III trials and a meta-analysis showed that induction ther- patients, a sequential approach is a reasonable option
apy followed by surgery might be better than surgery [26].
alone [20]. Surgery has been compared to radiotherapy • There is no role for prophylactic cranial irradiation in
in patients with tumor response after induction chemo- stage III (II,A).
therapy, without differences in overall survival [21]. Sur- • In patients with no progressive disease after concurrent
gery was also compared to radiotherapy after induction chemoradiotherapy, consolidation treatment with Dur-
chemoradiot

=== Population Extract 40 (Patients) ===
ed by surgery might be better than surgery [26].
alone [20]. Surgery has been compared to radiotherapy • There is no role for prophylactic cranial irradiation in
in patients with tumor response after induction chemo- stage III (II,A).
therapy, without differences in overall survival [21]. Sur- • In patients with no progressive disease after concurrent
gery was also compared to radiotherapy after induction chemoradiotherapy, consolidation treatment with Dur-
chemoradiotherapy in the Lung Intergroup Trial 0139 valumab for 1 year has shown to improve progression-
showing better progression-free survival

=== Population Extract 41 (Patients) ===
l 0139 valumab for 1 year has shown to improve progression-
showing better progression-free survival in the surgery free survival (PFS) and OS (I,A) [27–29]. The European
arm, with no differences in OS except in the unplanned Medical Agency has recently approved consolida-
analysis in the subset of patients who underwent lobec- tion with Durvalumab in patients with PD-L1 expres-
tomy [22]. The optimal chemotherapy regimen has not sion ≥ 1% based on an unplanned post hoc analysis.
been established in randomized trials, although cisplatin-
based chemotherapy is recommended.
• In case of superior sulcus

=== Population Extract 42 (Patients) ===
sion-
showing better progression-free survival in the surgery free survival (PFS) and OS (I,A) [27–29]. The European
arm, with no differences in OS except in the unplanned Medical Agency has recently approved consolida-
analysis in the subset of patients who underwent lobec- tion with Durvalumab in patients with PD-L1 expres-
tomy [22]. The optimal chemotherapy regimen has not sion ≥ 1% based on an unplanned post hoc analysis.
been established in randomized trials, although cisplatin-
based chemotherapy is recommended.
• In case of superior sulcus (Pancoast) tumors, concur-
rent chemoradiation followe

=== Population Extract 43 (Patients) ===
ery
Medically inoperable, n
Adjuvant chemotherapy
therapy)
Post operative radiother
Stage III
Completely resected
Potentially resectable
Unresectable stage III
Stage IV
Stage IV without driver m
Fist line
PD-L1 ≥ 50%
PD-L1 < 50% or unknow
Squamous cell carcinoma
Non-squamous-cell carcin
Elderly
Fit patients
Unfit or comorbidities
PS 2
PS 3–4
Oncology
ommend
y
node neg
y (four c
rapy (PO
mutation
wn
a (SCC)
noma (n
y (2019)
dations
gative N
cycles o
ORT)
ns
non-SC
NSCLC
of cispla
CC)
tumour
atin-base
rs ≤ 5 cm
ed chem
m
mo-
WHO classification for pathological diagnosis is required and also
IASLC classi

=== Population Extract 44 (Patients) ===
tion for pathological diagnosis is required and also
IASLC classification of adenocarcinoma
For therapeutic implications, specific subtyping of NSCLC is strong
recommended
Molecular testing in stage IV non-SCC should include EGFR muta-
tions, ALK and ROS-1 translocations by a validated technique
In patients progressing to first or second generation EGFR TKI dete
nation of EGFR T790M in plasma or tissue should be performed
PD-L1 expression should be test to all patients with advanced NSCL
at baseline
Comprehensive evaluation must include thorax and upper abdomen
More extensive evaluations are recommend

=== Population Extract 45 (Patients) ===
mended
Molecular testing in stage IV non-SCC should include EGFR muta-
tions, ALK and ROS-1 translocations by a validated technique
In patients progressing to first or second generation EGFR TKI dete
nation of EGFR T790M in plasma or tissue should be performed
PD-L1 expression should be test to all patients with advanced NSCL
at baseline
Comprehensive evaluation must include thorax and upper abdomen
More extensive evaluations are recommended if a radical approach i
considered
Stage disease must be classified using the TNM 8th edition
Patients should be evaluated in a multidisciplinary tumor board
Lobe

=== Population Extract 46 (Patients) ===
should be performed
PD-L1 expression should be test to all patients with advanced NSCL
at baseline
Comprehensive evaluation must include thorax and upper abdomen
More extensive evaluations are recommended if a radical approach i
considered
Stage disease must be classified using the TNM 8th edition
Patients should be evaluated in a multidisciplinary tumor board
Lobectomy or anatomic pulmonary resection plus systematic media
nal lymph node dissection
SART
Recommended in stage II
Not recommended in stage I 7th TNM edition (except T > 4 cm)
Not indicated in completely resected stage I–II
Treatment decisi

=== Population Extract 47 (Patients) ===
s for 3 years and annually thereafter
PET–CT ± biopsy if recurrence is suspected
Early palliative care
Evaluation of response every 6–12 weeks
or greater (tumor proportion score (TPS) ≥ 50%), pem-
brolizumab is recommended in the absence of contrain-
dications to use immunotherapy [30] (I,A).
• For patients with low (TPS < 50%) or unknown PD-L1
expression, chemotherapy with platinum doublets should
be considered in all stage IV PS 0–1 NSCLCs without
ver driver mutations (I,A). Data have shown that platinum
0% combination therapy increases OS and improves quality PS 0-1 PS 2 PS 3-4
PD-L1≥ 50%
PD-L1< 50

=== Population Extract 48 (Patients) ===
ss of the PD-L1 status [37–41] (I,A-I,B). is important to underline that these combinations were
• Cisplatin-based combinations and some modalities of not approved by the European Medical Agency when this
treatment will be selected based on tumor histology: guideline was submitted. • For PS 0–1 SCC patients, without major comorbidities • Any platinum-based doublets with a third-genera-
and with low (TPS < 50%) or unknown PD-L1, platinum- tion agent can be used in non-SCC patients with low
based doublets with the addition of a third-generation (TPS < 50%) or unknown PD-L1 [42] (I,A).
cytotoxic agent (g

=== Population Extract 49 (Patients) ===
ean Medical Agency when this
treatment will be selected based on tumor histology: guideline was submitted. • For PS 0–1 SCC patients, without major comorbidities • Any platinum-based doublets with a third-genera-
and with low (TPS < 50%) or unknown PD-L1, platinum- tion agent can be used in non-SCC patients with low
based doublets with the addition of a third-generation (TPS < 50%) or unknown PD-L1 [42] (I,A).
cytotoxic agent (gemcitabine, vinorelbine, taxanes) are • Pemetrexed-based combination chemotherapy represents
recommended (I,A). The different combinations have a therapeutic option. This regim

=== Population Extract 50 (Patients) ===
ble efficacy [42]. significant survival benefit compared with gemcitabine
• Four cycles are recommended, up to a maximum of six or docetaxel-based combinations (results coming from a
cycles in selected cases [43, 44] (I,A).
meta-analysis and a preplanned subgroup analysis of a particularly in those patients progressing within 9 months
randomized phase III trial) [46, 47] (II,A). after start of first-line therapy [55] (II,B).
• Bevacizumab/paclitaxel/carboplatin combination chem- • Docetaxel, or pemetrexed have demonstrated improve-
otherapy followed by maintenance bevacizumab has ment in terms of OS a

=== Population Extract 51 (Patients) ===
-line therapy [55] (II,B).
• Bevacizumab/paclitaxel/carboplatin combination chem- • Docetaxel, or pemetrexed have demonstrated improve-
otherapy followed by maintenance bevacizumab has ment in terms of OS and QoL (I,B) and are recommended
shown improvement in OS in two randomized clinical for those patients with contraindications to immunother-
trials and, therefore, it can be offered to patients with apy or nintedanib combination therapy (non-SCC) [56,
advanced PS 0–1 non-SCC and no contraindications for 57].
antiangiogenic treatment [6, 48] (I,A). • In patients who have received an immune checkpoint

=== Population Extract 52 (Patients) ===
el, or pemetrexed have demonstrated improve-
otherapy followed by maintenance bevacizumab has ment in terms of OS and QoL (I,B) and are recommended
shown improvement in OS in two randomized clinical for those patients with contraindications to immunother-
trials and, therefore, it can be offered to patients with apy or nintedanib combination therapy (non-SCC) [56,
advanced PS 0–1 non-SCC and no contraindications for 57].
antiangiogenic treatment [6, 48] (I,A). • In patients who have received an immune checkpoint
• Maintenance therapy can be considered in those PS 0–1 inhibitor as first-line therapy, p

=== Population Extract 53 (Patients) ===
S in two randomized clinical for those patients with contraindications to immunother-
trials and, therefore, it can be offered to patients with apy or nintedanib combination therapy (non-SCC) [56,
advanced PS 0–1 non-SCC and no contraindications for 57].
antiangiogenic treatment [6, 48] (I,A). • In patients who have received an immune checkpoint
• Maintenance therapy can be considered in those PS 0–1 inhibitor as first-line therapy, platinum doublets are rec-
patients with at least stable disease and who have recov- ommended (I,B).
ered from residual toxicity after first-line chemotherapy: • For those

=== Population Extract 54 (Patients) ===
mbination therapy (non-SCC) [56,
advanced PS 0–1 non-SCC and no contraindications for 57].
antiangiogenic treatment [6, 48] (I,A). • In patients who have received an immune checkpoint
• Maintenance therapy can be considered in those PS 0–1 inhibitor as first-line therapy, platinum doublets are rec-
patients with at least stable disease and who have recov- ommended (I,B).
ered from residual toxicity after first-line chemotherapy: • For those patients who have received first-line conven-
tional chemotherapyand immune therapy, single agent,
• Pemetrexed switch maintenance could be considered docetaxel, p

=== Population Extract 55 (Patients) ===
who have received an immune checkpoint
• Maintenance therapy can be considered in those PS 0–1 inhibitor as first-line therapy, platinum doublets are rec-
patients with at least stable disease and who have recov- ommended (I,B).
ered from residual toxicity after first-line chemotherapy: • For those patients who have received first-line conven-
tional chemotherapyand immune therapy, single agent,
• Pemetrexed switch maintenance could be considered docetaxel, pemetrexed (non-SCC) or docetaxel plus nin-
after four cycles of non-pemetrexed platinum-based tedanib (non-SCC) could be considered (IIB).
chemot

=== Population Extract 56 (Patients) ===
cetaxel plus nin-
after four cycles of non-pemetrexed platinum-based tedanib (non-SCC) could be considered (IIB).
chemotherapy [49] (I,B). • There is no sufficient evidence to recommend the use of
• Pemetrexed continuation maintenance should be con- cytotoxic drugs as fourth-line therapy or beyond; patients
sidered in patients having disease control after four should be considered to be included in clinical trials, and
courses of pemetrexed platinum-based chemotherapy continued best supportive care.
[50] (I,A).
Elderly and PS2
• Recently, three randomized phase III trials have shown
that the addition

=== Population Extract 57 (Patients) ===
ter four cycles of non-pemetrexed platinum-based tedanib (non-SCC) could be considered (IIB).
chemotherapy [49] (I,B). • There is no sufficient evidence to recommend the use of
• Pemetrexed continuation maintenance should be con- cytotoxic drugs as fourth-line therapy or beyond; patients
sidered in patients having disease control after four should be considered to be included in clinical trials, and
courses of pemetrexed platinum-based chemotherapy continued best supportive care.
[50] (I,A).
Elderly and PS2
• Recently, three randomized phase III trials have shown
that the addition of immunotherapy (pe

=== Population Extract 58 (Patients) ===
m- ment selection, and Comprehensive Geriatric Assessment
etrexed platinum-based combination or bevacizumab would help to ascertain the true biological status [58].
plus chemotherapy) in non-SCC resulted in significantly
longer OS ± PFS than chemotherapy alone, regardless of • For those elderly fit patients with PS 0–1 and adequate
PD-L1 expression [37, 39, 41]. It is important to under- organ function, first-line treatment decision should be
line that pembrolizumab with pemetrexed and platinum- based according to histology and PD-L1 expression lev-
based chemotherapy was the only combination approved

=== Population Extract 59 (Patients) ===
ccording to histology and PD-L1 expression lev-
based chemotherapy was the only combination approved els [59] (I,B). Single agent chemotherapy (vinorelbine,
by the European Medical Agency when this guideline gemcitabine, docetaxel) is recommended for those with
was submitted. comorbidities or unfit patients [60] (IB).
• For patients with PS 2, chemotherapy prolongs OS
compared to best supportive care (BSC) [61] (I,B). In
Second‑line therapy
an individualized-based decision, combination therapy,
single-agent therapy, or palliative therapy alone may be
Patients clinically or radiologically progressing a

=== Population Extract 60 (Patients) ===
PD-L1 expression lev-
based chemotherapy was the only combination approved els [59] (I,B). Single agent chemotherapy (vinorelbine,
by the European Medical Agency when this guideline gemcitabine, docetaxel) is recommended for those with
was submitted. comorbidities or unfit patients [60] (IB).
• For patients with PS 2, chemotherapy prolongs OS
compared to best supportive care (BSC) [61] (I,B). In
Second‑line therapy
an individualized-based decision, combination therapy,
single-agent therapy, or palliative therapy alone may be
Patients clinically or radiologically progressing after first- used for PS 2

=== Population Extract 61 (Patients) ===
with
was submitted. comorbidities or unfit patients [60] (IB).
• For patients with PS 2, chemotherapy prolongs OS
compared to best supportive care (BSC) [61] (I,B). In
Second‑line therapy
an individualized-based decision, combination therapy,
single-agent therapy, or palliative therapy alone may be
Patients clinically or radiologically progressing after first- used for PS 2 patients. In the first-line setting, platinum-
line therapy, with a PS 0–1 and appropriate PS 2, should be based doublets (preferably carboplatin) have superior
offered second-line treatment (I,A). Second-line treatment efficacy to

=== Population Extract 62 (Patients) ===
with PS 2, chemotherapy prolongs OS
compared to best supportive care (BSC) [61] (I,B). In
Second‑line therapy
an individualized-based decision, combination therapy,
single-agent therapy, or palliative therapy alone may be
Patients clinically or radiologically progressing after first- used for PS 2 patients. In the first-line setting, platinum-
line therapy, with a PS 0–1 and appropriate PS 2, should be based doublets (preferably carboplatin) have superior
offered second-line treatment (I,A). Second-line treatment efficacy to monotherapy, despite higher toxicity rates
should be individualized and trea

=== Population Extract 63 (Patients) ===
be based doublets (preferably carboplatin) have superior
offered second-line treatment (I,A). Second-line treatment efficacy to monotherapy, despite higher toxicity rates
should be individualized and treatment duration should be [62, 63] (II,A).
subject to tolerability and clinical benefit. • Unfit patients with PS 3–4 should not receive active treat-
ment regardless of age because no benefit has been dem-
• In patients with metastatic non-SCC and SCC who have onstrated. Supportive care is recommended (II,B).
not received prior immunotherapy, and with no con-
traindications, single-agent pembrolizumab

=== Population Extract 64 (Patients) ===
efficacy to monotherapy, despite higher toxicity rates
should be individualized and treatment duration should be [62, 63] (II,A).
subject to tolerability and clinical benefit. • Unfit patients with PS 3–4 should not receive active treat-
ment regardless of age because no benefit has been dem-
• In patients with metastatic non-SCC and SCC who have onstrated. Supportive care is recommended (II,B).
not received prior immunotherapy, and with no con-
traindications, single-agent pembrolizumab (PD-L1
Stage IV with driver mutations (Fig. 3)
TPS ≥ 1%), nivolumab or atezolizumab is recommended
(I,A). This rec

=== Population Extract 65 (Patients) ===
strategies (surgery or SBRT) and con(cid:31)nue with targeted therapy (II,A)
Fig. 3 Treatment algorithm for Stage IV with known targetable drivers
based doublets (I,A) [64, 65]. Only a prespecified suba- After EGFR TKI progression
nalysis showed a significant improvement in OS favoring
afatinib in patients with Del19 mutations [65]. • Patients might benefit of continuation with the EGFR TKI,
• Patients with PS 3–4 may also be offered an EGFR TKI, especially if clinical benefit is maintained from a sustained
as they are likely to receive a similar clinical benefit to EGFR oncogenic blockade [7] or if

=== Population Extract 66 (Patients) ===
cid:31)nue with targeted therapy (II,A)
Fig. 3 Treatment algorithm for Stage IV with known targetable drivers
based doublets (I,A) [64, 65]. Only a prespecified suba- After EGFR TKI progression
nalysis showed a significant improvement in OS favoring
afatinib in patients with Del19 mutations [65]. • Patients might benefit of continuation with the EGFR TKI,
• Patients with PS 3–4 may also be offered an EGFR TKI, especially if clinical benefit is maintained from a sustained
as they are likely to receive a similar clinical benefit to EGFR oncogenic blockade [7] or if there is an oligopro-
patients with go

=== Population Extract 67 (Patients) ===
orithm for Stage IV with known targetable drivers
based doublets (I,A) [64, 65]. Only a prespecified suba- After EGFR TKI progression
nalysis showed a significant improvement in OS favoring
afatinib in patients with Del19 mutations [65]. • Patients might benefit of continuation with the EGFR TKI,
• Patients with PS 3–4 may also be offered an EGFR TKI, especially if clinical benefit is maintained from a sustained
as they are likely to receive a similar clinical benefit to EGFR oncogenic blockade [7] or if there is an oligopro-
patients with good PS (III,A). gressive disease treatable with local strateg

=== Population Extract 68 (Patients) ===
[65]. • Patients might benefit of continuation with the EGFR TKI,
• Patients with PS 3–4 may also be offered an EGFR TKI, especially if clinical benefit is maintained from a sustained
as they are likely to receive a similar clinical benefit to EGFR oncogenic blockade [7] or if there is an oligopro-
patients with good PS (III,A). gressive disease treatable with local strategies (SART or
• Results from direct comparison of first-, second- and surgery) (II,A) [75].
third-generation EGFR TKIs in previously untreated • EGFR Exon 20, T790 M mutation, is the main mecha-
patients have been reported. Although

=== Population Extract 69 (Patients) ===
] or if there is an oligopro-
patients with good PS (III,A). gressive disease treatable with local strategies (SART or
• Results from direct comparison of first-, second- and surgery) (II,A) [75].
third-generation EGFR TKIs in previously untreated • EGFR Exon 20, T790 M mutation, is the main mecha-
patients have been reported. Although a benefit in terms nism of acquired resistance after first- or second-generation
of PFS has been demonstrated for third-generation TKIs EGFR TKIs [76]. Osimertinib has demonstrated greater
osimertinib (I,A) and dacomitinib (I,A) [66–68], to date efficacy over platinum-b

=== Population Extract 70 (Patients) ===
or second-generation
of PFS has been demonstrated for third-generation TKIs EGFR TKIs [76]. Osimertinib has demonstrated greater
osimertinib (I,A) and dacomitinib (I,A) [66–68], to date efficacy over platinum-based chemotherapy (I,A) [77].
only dacomitinib has shown a significant OS advantage • For patients with systemic symptomatic progression
(I,A) [69]. However, grade 3–4 treatment-related adverse in whom T790 M cannot be detected or who have pro-
events were significantly higher with dacomitinib. OS gressed to osimertinib, platinum-based chemotherapy
data from the FLAURA trial comparing osimertini

=== Population Extract 71 (Patients) ===
of care (II,A). The combination of
sus standard of care are still immature [67]. atezolizumab plus bevacizumab plus chemotherapy has
• An exploratory data on brain disease suggest that the demonstrated a significant PFS benefit in the subgroup
probability of experiencing a progression on central of patients with EGFR mutation (III,A) [50].
nervous system (CNS) was lower with osimertinib and • Continuation of EGFR TKI with platinum-based chemo-
provided a higher intracranial activity (II,B) [70]. therapy does not impact on PFS nor on OS [78] (I,A).
• Combinations of bevacizumab and erlotinib were also

=== Population Extract 72 (Patients) ===
rapy in randomized phase
III trials (I,A) [79, 80]. • Crizotinib is indicated for the treatment of ROS-1-pos-
• Alectinib (I,A) and brigatinib (I,B) have shown a signifi- itive advanced NSCLC based on the results of a single-
cant improvement in PFS versus crizotinib and, therefore, arm trial in 50 patients [90] (III,A).
are the preferred first-line options. Grade 3–5 adverse • Dabrafenib–Trametinib is indicated for the treatment
events were higher for patients treated with crizotinib of advanced NSCLC BRAFV600E mutation based on
[81, 82]. It is important to underline that brigatinib was results from

=== Population Extract 73 (Patients) ===
wn a signifi- itive advanced NSCLC based on the results of a single-
cant improvement in PFS versus crizotinib and, therefore, arm trial in 50 patients [90] (III,A).
are the preferred first-line options. Grade 3–5 adverse • Dabrafenib–Trametinib is indicated for the treatment
events were higher for patients treated with crizotinib of advanced NSCLC BRAFV600E mutation based on
[81, 82]. It is important to underline that brigatinib was results from non-comparative studies in pretreated or
not approved by the European Medical Agency when this naïve patients [91, 92] (II,A).
guideline was submitted. • New

=== Population Extract 74 (Patients) ===
icated for the treatment
events were higher for patients treated with crizotinib of advanced NSCLC BRAFV600E mutation based on
[81, 82]. It is important to underline that brigatinib was results from non-comparative studies in pretreated or
not approved by the European Medical Agency when this naïve patients [91, 92] (II,A).
guideline was submitted. • New investigational drugs have shown activity in
• Chemotherapy is indicated (III,B) in patients whose ALK early clinical trials targeting oncogenic drivers such
results are not available and urgent systemic treatment as crizotinib, tepotinib or capmatini

=== Population Extract 75 (Patients) ===
s important to underline that brigatinib was results from non-comparative studies in pretreated or
not approved by the European Medical Agency when this naïve patients [91, 92] (II,A).
guideline was submitted. • New investigational drugs have shown activity in
• Chemotherapy is indicated (III,B) in patients whose ALK early clinical trials targeting oncogenic drivers such
results are not available and urgent systemic treatment as crizotinib, tepotinib or capmatinib (MET amplified,
is required. Treatment plan should be reassured when M ETe14 mutation), LOXO-292 and BLU-667 (RET),
genotypic results were

=== Population Extract 76 (Patients) ===
esults are not available and urgent systemic treatment as crizotinib, tepotinib or capmatinib (MET amplified,
is required. Treatment plan should be reassured when M ETe14 mutation), LOXO-292 and BLU-667 (RET),
genotypic results were available. entrectinib (NRTK, ROS, ALK fusions), LOXO-101 or
• For patients who received chemotherapy in the first-line, larotrectinib (NRTK fusions) [93] and ado-trastuzumab
crizotinib should be recommended as second-line treat- emtansine (HER2 mutations). However, none of these
ment (I,A) [83]. Alectinib and ceritinib should also be targeted drugs have an official regula

=== Population Extract 77 (Patients) ===
sine (HER2 mutations). However, none of these
ment (I,A) [83]. Alectinib and ceritinib should also be targeted drugs have an official regulatory approval by
considered, although no specific trials have been con- EMA except the orphan drug designation of LOXO-101
ducted. in NTRK fusion tumors. • For patients who develop resistance or are intolerant
to crizotinib, ceritinib (IA), alectinib (IA) or brigatinib
The oligometastatic state consists of patients with metasta-
(IIA) can be recommended. Ceritinib and alectinib have
sis limited in number and location. The number of metas-
shown a significant impro

=== Population Extract 78 (Patients) ===
roval by
considered, although no specific trials have been con- EMA except the orphan drug designation of LOXO-101
ducted. in NTRK fusion tumors. • For patients who develop resistance or are intolerant
to crizotinib, ceritinib (IA), alectinib (IA) or brigatinib
The oligometastatic state consists of patients with metasta-
(IIA) can be recommended. Ceritinib and alectinib have
sis limited in number and location. The number of metas-
shown a significant improvement in median PFS and less
tases ranges from a single metastatic lesion to a single
adverse events than chemotherapy. Brigatinib has shown
organ

=== Population Extract 79 (Patients) ===
tinib has shown
organ with multiple metastases or to multiple lesions in
a favorable PFS in a crizotinib-refractory ALK-positive
multiple organs. The most accepted number of metastatic
phase II trial [84–86].
lesions is up to five and, most important, these should
• Lorlatinib has shown activity in patients who have pro-
be suitable to radical treatment by local therapy: surgi-
gressed on next-generation ALK TKI (ceritinib, alectinib
cal resection, SART or both. The oligometastatic disease
or brigatinib) [87] (II,A).
comprises four different settings [94]:
• Ensartinib and entrectinib have also been d

=== Population Extract 80 (Patients) ===
ment by local therapy: surgi-
gressed on next-generation ALK TKI (ceritinib, alectinib
cal resection, SART or both. The oligometastatic disease
or brigatinib) [87] (II,A).
comprises four different settings [94]:
• Ensartinib and entrectinib have also been demonstrated
activity in previously treated patients in early phase trials
1. Metastatic lesions limited in number and location at
diagnosis, all the lesions including the primary tumor
• For patients with systemic symptomatic progression to
are suitable to radical therapy.
ALK TKI, platinum-based chemotherapy remains the
2. Multiple metastases that

=== Population Extract 81 (Patients) ===
rigatinib) [87] (II,A).
comprises four different settings [94]:
• Ensartinib and entrectinib have also been demonstrated
activity in previously treated patients in early phase trials
1. Metastatic lesions limited in number and location at
diagnosis, all the lesions including the primary tumor
• For patients with systemic symptomatic progression to
are suitable to radical therapy.
ALK TKI, platinum-based chemotherapy remains the
2. Multiple metastases that are transformed into an oli-
standard of care (II,A). The combination of atezolizumab
gometastatic disease after systemic treatment due to
plus beva

=== Population Extract 82 (Patients) ===
nificant PFS benefit (III,B) [50].
intent.
3. The primary tumor and most areas of metastatic disease
Brain metastases
remain controlled, but one or a limited number of metas-
tases progress while systemic therapy.
• Alectinib, brigatinib and lorlatinib have showngreater 4. Oligorecurrence occurs in patients treated with cura-
activity in CNS disease. In the ALEX trial, fewer patients tive intent and metachronously present 1–5 metastastic
treated with alectinib (12%) had CNS progression than lesions suitable to ablative therapy.
crizotinib (45%). In the ALTA-1 trial, intracranial RR
• Patients with oli

=== Population Extract 83 (Patients) ===
of metastatic disease
Brain metastases
remain controlled, but one or a limited number of metas-
tases progress while systemic therapy.
• Alectinib, brigatinib and lorlatinib have showngreater 4. Oligorecurrence occurs in patients treated with cura-
activity in CNS disease. In the ALEX trial, fewer patients tive intent and metachronously present 1–5 metastastic
treated with alectinib (12%) had CNS progression than lesions suitable to ablative therapy.
crizotinib (45%). In the ALTA-1 trial, intracranial RR
• Patients with oligometastatic disease at diagno-
was 78% for brigatinib versus 29% for crizotin

=== Population Extract 84 (Patients) ===
ccurs in patients treated with cura-
activity in CNS disease. In the ALEX trial, fewer patients tive intent and metachronously present 1–5 metastastic
treated with alectinib (12%) had CNS progression than lesions suitable to ablative therapy.
crizotinib (45%). In the ALTA-1 trial, intracranial RR
• Patients with oligometastatic disease at diagno-
was 78% for brigatinib versus 29% for crizotinib [82].
sis should be treated with systemic therapy and
• For asymptomatic or patients who became asymptomatic
local consolidative ablative therapy (LAT) to pri-
with steroids, brain-penetrable ALK TKIs may be us

=== Population Extract 85 (Patients) ===
(12%) had CNS progression than lesions suitable to ablative therapy.
crizotinib (45%). In the ALTA-1 trial, intracranial RR
• Patients with oligometastatic disease at diagno-
was 78% for brigatinib versus 29% for crizotinib [82].
sis should be treated with systemic therapy and
• For asymptomatic or patients who became asymptomatic
local consolidative ablative therapy (LAT) to pri-
with steroids, brain-penetrable ALK TKIs may be used
mary and all metastatic sites. Two phase II studies
and local treatments may be deferred (I,B).
showed that LAT after systemic therapy increased Novartis, Tesaro, outside

=== Population Extract 86 (Patients) ===
(I,B).
showed that LAT after systemic therapy increased Novartis, Tesaro, outside the submitted work. OJ reports grants from
PFS vs no further local treatment [95, 96] (I,A). Astra Zeneca and personal fees from Astra Zeneca, BMS, MSD,
ROCHE, Boehringer Ingelheim, Lilly outside the submitted work.
• Patients with actionable mutations receiving targeted
MP reports grants from BMS, Roche and personal fees from BMS,
therapies who progress on isolated site can be treated MSD, ROCHE, Pierre Fabre, Novartis; Takeda, Lilly, Pfizer outside
with LAT [75, 97] (II,A). the submitted work. NR reports advisory Board

=== Population Extract 87 (Patients) ===
om ARIAD, AstraZeneca, Roche, Pfizer, BMS,
may impact on drugs’ bioavailability (II,A).
Boehringer Ingelheim, MSD outside the submitted work. YG reports
• There is not an established consensus regarding the most personal fees from Roche, Boehriger-ingelheim, Lilly, MSD, Pfizer,
optimal follow-up in patients with NSCLC. However, due BMS outside the submitted work. JMT reports personal fees from
to the inherent aggressiveness of the disease, a close fol- Roche, Boehriger-ingelheim, BMS, Astra Zeneca, MerckSerono out-
side the submitted work. AI, EC, MG, have not reported any potential
low-up is advised.

=== Population Extract 88 (Patients) ===
the submitted work. JMT reports personal fees from
to the inherent aggressiveness of the disease, a close fol- Roche, Boehriger-ingelheim, BMS, Astra Zeneca, MerckSerono out-
side the submitted work. AI, EC, MG, have not reported any potential
low-up is advised.
conflicts of interest.
Follow up in patients after curative treatment: Ethical approval The current study has been performed in accordance
with the ethical standards laid down in the 1964 Declaration of Hel-
sinki and its later amendments.
• NSCLC patients treated with radical intent must be fol-
lowed to identify treatment-related complicati

=== Population Extract 89 (Patients) ===
have not reported any potential
low-up is advised.
conflicts of interest.
Follow up in patients after curative treatment: Ethical approval The current study has been performed in accordance
with the ethical standards laid down in the 1964 Declaration of Hel-
sinki and its later amendments.
• NSCLC patients treated with radical intent must be fol-
lowed to identify treatment-related complications, detec- Informed consent No informed consent was necessary for this guide-
tion of treatable relapse or occurrence of second primary line.
lung cancer (III,A).
• In patients with curative surgery, a close fol

=== Population Extract 90 (Patients) ===
and its later amendments.
• NSCLC patients treated with radical intent must be fol-
lowed to identify treatment-related complications, detec- Informed consent No informed consent was necessary for this guide-
tion of treatable relapse or occurrence of second primary line.
lung cancer (III,A).
• In patients with curative surgery, a close follow-up visit Open Access This article is distributed under the terms of the Crea-
including medical history, physical examination and chest tive Commons Attribution 4.0 International License  veco
CT is recommended every 6–12 months for the first 2 years mmons. org

=== Population Extract 91 (Patients) ===
ommended every 6–12 months for the first 2 years mmons. org/licens es/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate
and annually thereafter (III,B).
credit to the original author(s) and the source, provide a link to the
• For patients treated with SART with radical intent, CT Creative Commons license, and indicate if changes were made.
scans every 6 months for 3 years are recommended and
annually thereafter (III,B). PET–CT ± biopsy is endorsed
when recurrence is suspected based on chest CT To dis-
References
criminate from focal

=== Population Extract 92 (Patients) ===
lance with blood test, FDG-PET imaging
1. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM,
or another radiological assessment is not endorsed (II,D).
Beasley MB, et al. The 2015 World Health Organization clas-
sification of lung tumors: impact of genetic, clinical and radio-
Follow up in patients with advanced disease: logic advances since the 2004 classification. J Thorac Oncol.
2. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB,
• Early palliative care is strongly recommended [98] (I,A).
Bernicker EH, et al. Updated molecular testing guideline for
• Evaluation of response is recom

=== Population Extract 93 (Patients) ===
classification. J Thorac Oncol.
2. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB,
• Early palliative care is strongly recommended [98] (I,A).
Bernicker EH, et al. Updated molecular testing guideline for
• Evaluation of response is recommended every 6–12 weeks the selection of lung cancer patients for treatment with targeted
after therapy initiation, using the same baseline radio- tyrosine kinase inhibitors: guideline from the college of American
pathologists, the international association for the study of lung
graphic method. The frequency of the radiologic assess-
cancer, and the associati

=== Population Extract 94 (Patients) ===
ame baseline radio- tyrosine kinase inhibitors: guideline from the college of American
pathologists, the international association for the study of lung
graphic method. The frequency of the radiologic assess-
cancer, and the association for molecular pathology. J Mol Diagn.
ment can be tailored for patients benefiting long time on
targeted agents (III,B). 3. Felip E, Concha A, de Castro J, Gomez-Roman J, Garrido P, Ram-
• For patients eligible for successive lines that respond to irez J, et al. Biomarker testing in advanced non-small-cell lung
cancer: a national consensus of the spanish society of pat

=== Population Extract 95 (Patients) ===
for the study of lung
graphic method. The frequency of the radiologic assess-
cancer, and the association for molecular pathology. J Mol Diagn.
ment can be tailored for patients benefiting long time on
targeted agents (III,B). 3. Felip E, Concha A, de Castro J, Gomez-Roman J, Garrido P, Ram-
• For patients eligible for successive lines that respond to irez J, et al. Biomarker testing in advanced non-small-cell lung
cancer: a national consensus of the spanish society of pathology
first-line treatment, it is advisable to undergo clinical and/
and the spanish society of medical oncology. Clin Transl Onc

=== Population Extract 96 (Patients) ===
-cell lung cancer: ESMO clinical prac-
tice guidelines for diagnosis, treatment and follow-up. Ann Oncol.
2016;27(suppl 5):v1–27.
5. Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Don-
Compliance with ethical standards
ington J, Leighl NB, et al. Molecular testing guideline for the
selection of patients with lung cancer for treatment with targeted
Conflict of interest MM reports personal fees from AstraZeneca, tyrosine kinase inhibitors: American Society of Clinical Oncol-
Roche, Lilly, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, ogy endorsement of the College of American Pathozlogists/
In

=== Population Extract 97 (Patients) ===
ideline update. J 2008;26(21):3552–9.
Clin Oncol. 2018;36(9):911–9. 20. Burdett SS, Stewart LA, Rydzewska L. Chemotherapy and sur-
6. Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, gery versus surgery alone in non-small cell lung cancer. Cochrane
et al. Clinical activity of afatinib in patients with advanced non- Database Syst Rev. 2007. https: //doi.org/10.1002/146518 58.
small-cell lung cancer harbouring uncommon EGFR mutations: CD0061 57.pub2.
a combined post hoc analysis of LUX-Lung 2, LUX-Lung 3, and 21. van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C,
LUX-Lung 6. Lancet Oncol.

=== Population Extract 98 (Patients) ===
advanced non-small-cell lung cancer and Eastern coop- 76. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W,
erative oncology group performance status of 2. J Clin Oncol. et al. Analysis of tumor specimens at the time of acquired resist-
2013;31(23):2849–53. ance to EGFR-TKI therapy in 155 patients with EGFR-mutant
lung cancer: an open-label, phase 2 trial. Lancet Oncol. non-small-cell lung cancer without progression after first-line
2017;18(10):1307–16. systemic therapy: a multicentre, randomised, controlled, phase 2
92. Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik study. Lance

=== Population Extract 99 (Patients) ===
ol. non-small-cell lung cancer without progression after first-line
2017;18(10):1307–16. systemic therapy: a multicentre, randomised, controlled, phase 2
92. Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik study. Lancet Oncol. 2016;17(12):1672–82.
CS, et al. Dabrafenib plus trametinib in patients with previously 96. Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS,
treated BRAF(V600E)-mutant metastatic non-small cell lung et al. Consolidative radiotherapy for limited metastatic non-small-
cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. cell lung cancer: a phase 2 r

=== Population Extract 100 (Patients) ===
Ou SH, Janne PA, Bartlett CH, Tang Y, Kim DW, Otterson GA,
etri GD, et al. Efficacy of larotrectinib in TRK fusion-positive can- et al. Clinical benefit of continuing ALK inhibition with crizotinib
cers in adults and children. New Engl J Med. 2018;378(8):731–9. beyond initial disease progression in patients with advanced ALK-
94. Juan O, Popat S. Ablative therapy for oligometastatic non-small positive NSCLC. Ann Oncol. 2014;25(2):415–22.
cell lung cancer. Clin Lung Cancer. 2017;18(6):595–606. 98. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane

=== Population Extract 101 (Adults) ===
984–93. 2018;4(1):e173501.
93. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Dem- 97. Ou SH, Janne PA, Bartlett CH, Tang Y, Kim DW, Otterson GA,
etri GD, et al. Efficacy of larotrectinib in TRK fusion-positive can- et al. Clinical benefit of continuing ALK inhibition with crizotinib
cers in adults and children. New Engl J Med. 2018;378(8):731–9. beyond initial disease progression in patients with advanced ALK-
94. Juan O, Popat S. Ablative therapy for oligometastatic non-small positive NSCLC. Ann Oncol. 2014;25(2):415–22.
cell lung cancer. Clin Lung Cancer. 2017;18(6):595–606. 98. Temel JS,

